Skip to main content
. 2022 Feb 14;12:761558. doi: 10.3389/fonc.2022.761558

Figure 3.

Figure 3

Sequencing reads of PRRC2B and ALK visualized by the Integrative Genomics Viewer (IGV). (A) Next-generation sequencing identified PRRC2B-ALK fusion before crizotinib treatment. (B) A schematic map showing the structure of the PRRC2B-ALK fusion locus. The slash marks on the introns indicate the break points. Next-generation sequencing identified ALK R1192P after crizotinib resistance (C) and ALK L1196M after alectinib resistance (D).